Literature DB >> 25829250

Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Achilleas D Theocharis1, Spyros S Skandalis1, Thomas Neill2, Hinke A B Multhaupt3, Mario Hubo4, Helena Frey4, Sandeep Gopal3, Angélica Gomes3, Nikos Afratis3, Hooi Ching Lim3, John R Couchman3, Jorge Filmus5, Ralph D Sanderson6, Liliana Schaefer4, Renato V Iozzo2, Nikos K Karamanos7.   

Abstract

Proteoglycans control numerous normal and pathological processes, among which are morphogenesis, tissue repair, inflammation, vascularization and cancer metastasis. During tumor development and growth, proteoglycan expression is markedly modified in the tumor microenvironment. Altered expression of proteoglycans on tumor and stromal cell membranes affects cancer cell signaling, growth and survival, cell adhesion, migration and angiogenesis. Despite the high complexity and heterogeneity of breast cancer, the rapid evolution in our knowledge that proteoglycans are among the key players in the breast tumor microenvironment suggests their potential as pharmacological targets in this type of cancer. It has been recently suggested that pharmacological treatment may target proteoglycan metabolism, their utilization as targets for immunotherapy or their direct use as therapeutic agents. The diversity inherent in the proteoglycans that will be presented herein provides the potential for multiple layers of regulation of breast tumor behavior. This review summarizes recent developments concerning the biology of selected proteoglycans in breast cancer, and presents potential targeted therapeutic approaches based on their novel key roles in breast cancer.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Decorin; Glypicans; Proteoglycans; Serglycin; Syndecans

Mesh:

Substances:

Year:  2015        PMID: 25829250      PMCID: PMC4433619          DOI: 10.1016/j.bbcan.2015.03.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  365 in total

1.  Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.

Authors:  Dingcheng Gao; Natasha Joshi; Hyejin Choi; Seongho Ryu; Mary Hahn; Raul Catena; Helen Sadik; Pedram Argani; Patrick Wagner; Linda T Vahdat; Jeffrey L Port; Brendon Stiles; Saraswati Sukumar; Nasser K Altorki; Shahin Rafii; Vivek Mittal
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells.

Authors:  Philip K Lim; Sarah A Bliss; Shyam A Patel; Marcelo Taborga; Meneka A Dave; Larissa A Gregory; Steven J Greco; Margarette Bryan; Prem S Patel; Pranela Rameshwar
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

3.  Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.

Authors:  Sean C Dowdy; Bobbie S Gostout; Viji Shridhar; Xiaosheng Wu; David I Smith; Karl C Podratz; Shi-Wen Jiang
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

4.  A role for versican in the development of leiomyosarcoma.

Authors:  Paul A Keire; Steven L Bressler; Joan M Lemire; Badreddin Edris; Brian P Rubin; Maziar Rahmani; Bruce M McManus; Matt van de Rijn; Thomas N Wight
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

5.  Resistance to Lyme disease in decorin-deficient mice.

Authors:  E L Brown; R M Wooten; B J Johnson; R V Iozzo; A Smith; M C Dolan; B P Guo; J J Weis; M Höök
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

6.  Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.

Authors:  F Echtermeyer; M Streit; S Wilcox-Adelman; S Saoncella; F Denhez; M Detmar; P Goetinck
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

7.  Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.

Authors:  Wei Gao; Heungnam Kim; Mingqian Feng; Yen Phung; Charles P Xavier; Jeffrey S Rubin; Mitchell Ho
Journal:  Hepatology       Date:  2014-06-18       Impact factor: 17.425

8.  Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells.

Authors:  Takashi Maeda; Caroline M Alexander; Andreas Friedl
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Jiansheng Wu; Yong Q Chen; Isabelle M Berquin; Donna Perry; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

10.  Syndecan-4 phosphorylation is a control point for integrin recycling.

Authors:  Mark R Morgan; Hellyeh Hamidi; Mark D Bass; Stacey Warwood; Christoph Ballestrem; Martin J Humphries
Journal:  Dev Cell       Date:  2013-02-28       Impact factor: 12.270

View more
  54 in total

Review 1.  Decoding the Matrix: Instructive Roles of Proteoglycan Receptors.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Biochemistry       Date:  2015-07-22       Impact factor: 3.162

2.  The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density.

Authors:  Kylie L Gorringe; Ian G Campbell; Dane Cheasley; Lisa Devereux; Siobhan Hughes; Carolyn Nickson; Pietro Procopio; Grant Lee; Na Li; Vicki Pridmore; Kenneth Elder; G Bruce Mann; Tanjina Kader; Simone M Rowley; Stephen B Fox; David Byrne; Hugo Saunders; Kenji M Fujihara; Belle Lim
Journal:  NPJ Breast Cancer       Date:  2020-08-07

Review 3.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Authors:  Vishnu C Ramani; Israel Vlodavsky; Mary Ng; Yi Zhang; Paola Barbieri; Alessandro Noseda; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2016-03-22       Impact factor: 11.583

Review 5.  Proteoglycan-driven Autophagy: A Nutrient-independent Mechanism to Control Intracellular Catabolism.

Authors:  Thomas Neill; Simone Buraschi; Aastha Kapoor; Renato V Iozzo
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 6.  The role of heparins and nano-heparins as therapeutic tool in breast cancer.

Authors:  Nikos A Afratis; Konstantina Karamanou; Zoi Piperigkou; Demitrios H Vynios; Achilleas D Theocharis
Journal:  Glycoconj J       Date:  2016-10-24       Impact factor: 2.916

Review 7.  Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology.

Authors:  Liliana Schaefer; Claudia Tredup; Maria A Gubbiotti; Renato V Iozzo
Journal:  FEBS J       Date:  2016-12-07       Impact factor: 5.542

Review 8.  Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions.

Authors:  Maria A Gubbiotti; Sylvain D Vallet; Sylvie Ricard-Blum; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-09-30       Impact factor: 11.583

Review 9.  A current view of perlecan in physiology and pathology: A mosaic of functions.

Authors:  Maria A Gubbiotti; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-09-06       Impact factor: 11.583

Review 10.  Decorin as a multivalent therapeutic agent against cancer.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Adv Drug Deliv Rev       Date:  2015-10-30       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.